Policy & Updates
Kela Raises Income Limit by €400: Interest-Free Medical Credit Gets an Upgrade

In a move set to ease the financial burden of high prescription costs, Kela (the Social Insurance Institution of Finland) has announced a significant change to its interest-free medical credit. Starting in early 2027, the monthly income limit for the loan will rise from €1,800 to €2,200—a boost of €400 that will make more low-income residents eligible for help.
What Exactly Is the Medical Credit?
The medical credit (known in Finnish as lääkeluotto) isn't a traditional social benefit or a handout. It's a loan designed for people who struggle to pay a large sum for their prescription medicines all at once. The key difference from a normal loan? Kela charges zero interest. There are also no hidden fees, no setup costs, and no processing charges.
How It Works
The credit is meant for situations where a person has to pay the full annual out-of-pocket maximum for Kela-reimbursed prescription medicines in a single go or within one calendar month. The loan is then paid back in 12 equal monthly instalments.
The annual out-of-pocket cap (often called the medicine ceiling) is €636.12 in 2026, and it will rise to €650.56 in 2027. For someone paying back the full amount over a year, that works out to roughly €54 per month.
The pilot scheme for this interest-free credit was launched by Prime Minister Petteri Orpo's government in October 2025. It is a three-year trial aimed at helping low-income households cope with the cost of necessary medicines.
Who Qualifies?
To be eligible, your monthly earned income and benefits must not exceed the income limit. Currently, that limit is €1,800 for a single person, but it increases by €100 for each dependent child (up to five children).
Crucially, you cannot have the right to social assistance, as those costs are already covered by that benefit. You also must apply for the credit before you pay for the medicines—it cannot be claimed retroactively.
A Helping Hand, Not a Solution
While the raised limit is welcome news, it's important to remember that this is still a loan, not a grant. It offers breathing room for those facing sudden, high medication costs, but it must be repaid. The pilot will continue to be developed over its three-year run to see how it can best support those who need it most.